News

The battle against Parkinson’s disease may be getting sweeter, with a new study underway seeking to understand if concentrated chocolate supplements could help alleviate the disease’s symptoms. A team of researchers from Dresden University of Technology, Germany, are busy conducting tests on 30 participants to further understand the benefits of phenylethylamine, a compound found…

Four years ago, in 2011, science journalist Jon Palfreman went to see his physician about the tremors he had been experiencing in his left hand. It was then, at 60 years of age, that Jon found out he already had Parkinson’s disease, a neurodegenerative disorder that causes a gradual loss…

Clinical stage biopharmaceutical company, Anavex Life Sciences Corp., recently announced that it received a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to fund the advancement of ANAVEX 2-73 – a candidate drug for Parkinson’s…

A multidisciplinary team of researchers from the Sheffield Institute of Translational Neuroscience (SITraN), in collaboration with scientists from the University of York, have recently released results from a study that supports the fast-tracking of the drug ursodeoxycholic acid (UDCA), which has already been in use for decades to…

Recently, researchers from the National Institutes of Health’s (NIH) National Institute of Neurological Disorders and Stroke (NINDS) released results from X-ray crystalography analysis of the the neuropeptide hormone neurotensin, which has been shown to be involved in Parkinson’s Disease (PD).  Their research resulted in the first images showing how…

The National Parkinson Foundation, originally founded in 1957 and committed to helping patients diagnosed with Parkinson’s disease live a better, fuller life, has just announced the official relaunch of their website, featuring a brand new design that facilitates visitors’ awareness and knowledge of the disease. The website now offers free…

A new study led by researchers at the University of Barcelona in Spain recently revealed the reason behind discrepant outcomes when administering antagonist drugs for brain disorders. The study was published in the journal Proceedings of the National Academy of Sciences (PNAS) and is entitled “…

Parkinson’s disease is still the second most common neurodegenerative disorder affecting millions of people worldwide. A multidisciplinary team of researchers from UCL, the University of Cambridge and the University of Sheffield, have recently published a study in Nature Neuroscience linking a Parkinson’s disease-causing mutation in the Fbx07 gene…

Neurodegenerative diseases correspond to a range of debilitating conditions that primarily result in the degeneration and/or death of brain and spinal cord neurons. Parkinson’s disease is one example of a progressive neurodegenerative disorder that develops gradually, with patients usually experiencing the first symptoms around the age of 60 or older.

Recently, a group of researchers from the Buck Institute for Age Research in Novato, California released study results in which they found that low-dose lithium reduced involuntary motor movements – the troubling side effect of the medication most commonly used to treat Parkinson’s disease (PD). The study, entitled, “…